APEN - APEN STOCK NEWS

Apollo Endosurgery has announced a transition in leadership, appointing Charles McKhann as the new CEO effective March 1, 2021. Current CEO Todd Newton will assist in the transition and act as a consultant for the next six months. Under Newton, the company strengthened its balance sheet and positioned itself for growth, particularly with the upcoming launch of the X-Tack system. McKhann brings extensive medtech experience, having worked with firms like Boston Scientific and Johnson & Johnson. Apollo aims to leverage its innovative products to enhance gastrointestinal procedures.

Apollo Endosurgery (NASDAQ: APEN) announced its participation in the H.C. Wainwright Bioconnect 2021 Conference from January 11-14, 2021. The company will provide a pre-recorded presentation available on demand to registered investors. Additionally, management will conduct one-on-one meetings with institutional investors during the conference. Apollo specializes in less invasive medical devices for gastrointestinal and bariatric procedures, with products available in over 75 countries.

Apollo Endosurgery (NASDAQ:APEN) announced FDA 510(k) clearance of its X-Tack™ Endoscopic HeliX Tacking System on December 15, 2020. This innovative suture-based device addresses challenges in closing defects in the gastrointestinal tract, particularly large or irregular ones. A limited launch is set for January 2021, followed by a full launch in late Q1 2021. The device aims to enhance healing and reduce complications post-polypectomy, catering to the growing demand for minimally invasive procedures as around 20 million endoscopic procedures occur annually in the U.S.

Apollo Endosurgery (NASDAQ:APEN) announced an agreement to extend the interest-only period and maturity date of its term loan with Solar Capital Ltd. This extension, effective December 4, 2020, defers principal payments by 12 months, improving liquidity by approximately $12 million in 2021. Additionally, 99.25% of the company’s 6% convertible notes have been extended until August 12, 2026. CFO Stefanie Cavanaugh stated the extension strengthens liquidity and reduces the need for new equity financing before achieving positive cash flow.

Apollo Endosurgery (Nasdaq:APEN), a leader in less invasive medical devices, announced participation in the 32nd Annual Piper Sandler Healthcare Conference on December 1-2, 2020. The management will engage in virtual one-on-one meetings, with a pre-recorded fireside chat available for Piper Sandler clients. Investors wishing to attend or schedule meetings can contact their Piper Sandler representative or Apollo's investor relations.

Apollo specializes in device-based therapies for gastrointestinal conditions, operating in over 75 countries.

Apollo Endosurgery (NASDAQ:APEN) reported a 21% increase in total Endoscopy revenue for Q3 2020, reaching $12.5 million, driven by a resurgence in elective procedures as COVID-19 restrictions eased. U.S. Endoscopy sales rose 37% to $6.6 million, with improved gross margins at 55% compared to 48%70% to $2.6 million. Cash and equivalents totaled $38.2 million as of September 30, 2020. Apollo aims to leverage liquidity through 2021 while completing clinical trials and launching new products.

Austin, TX / Accesswire / November 3, 2020 / Apollo Endosurgery, Inc. (NASDAQ:APEN) announced participation in two investor conferences in November 2020. On November 17, they will engage in one-on-one meetings at the Craig Hallum Alpha Select Investor Conference. Following this, on November 19, they will present at the Sidoti Virtual Microcap Conference 2020 and conduct additional one-on-one meetings. Apollo specializes in less invasive medical devices for gastrointestinal and bariatric procedures, serving over 75 countries with advanced therapeutic options.

Apollo Endosurgery, Inc. (NASDAQ:APEN) will release its financial results for Q3 2020 on November 5, 2020, after U.S. market close. A conference call is scheduled for the same day at 3:30 p.m. CT to discuss the results. Participants can join by dialing +1-785-424-1667 or via a live webcast on the company’s investor relations page. Apollo specializes in less invasive medical devices for gastrointestinal and bariatric procedures, with products available in over 75 countries. For further details, visit www.apolloendo.com.

Apollo Endosurgery (NASDAQ: APEN) will present at the HC Wainwright & Co. Global Investment Conference on September 15, 2020, at 3:00 PM Eastern Time. CEO Todd Newton and CFO Stefanie Cavanaugh will lead the presentation and hold one-on-one meetings with qualified investors. Apollo specializes in less invasive medical devices for gastrointestinal and bariatric procedures, offering alternatives to traditional surgery. Their products are available in over 75 countries, including the OverStitch™ and ORBERA® systems.